文献速递角膜与眼表疾病

TFOS DEWS III:干眼病的管理与治疗

TFOS DEWS III: Management and Therapy.
PubMed 文献 · Am J Ophthalmol · 2025-06-02

本报告对当前干眼病(DED)管理策略进行了循证综述。一线管理聚焦于补充、保存和刺激泪膜,眼表补充剂仍是DED治疗的基石。睑板腺功能障碍通常采用热敷及多种诊室治疗,包括设备驱动眼睑加热、强脉冲光、低水平光疗等。TFOS DEWS III处方算法基于疾病病因提供循证框架,指导临床医生选择针对性干预措施。

要点

  • 一线管理聚焦补充、保存和刺激泪膜,眼表补充剂仍是DED治疗基石。
  • 睑板腺功能障碍通常采用热敷及诊室治疗,包括设备加热、强脉冲光、低水平光疗等。
  • TFOS DEWS III处方算法基于病因提供循证框架,指导选择针对性干预。

核心结论

  • TFOS DEWS III处方算法提供循证框架,指导临床医生基于疾病病因选择相关干预措施,以对个体所患DED亚型进行针对性管理。

研究设计与样本

  • 本报告为循证综述,系统回顾当前干眼病管理策略。

主要发现

  • 一线管理聚焦补充、保存和刺激泪膜的方法,强调眼表补充剂仍是DED治疗基石。
  • 睑板腺功能障碍作为DED主要贡献因素,通常采用热敷及多种诊室治疗,包括设备驱动眼睑加热技术、强脉冲光治疗、低水平光疗及其他新兴技术。
  • 睑缘清洁治疗包括睑缘湿巾、抗蠕形螨治疗、睑缘剥脱及局部抗生素。
  • 由特定病因驱动的DED可从抗炎治疗中获益,包括局部和口服皮质类固醇、T细胞免疫调节药物及多种药理制剂,此外还有生物泪液替代品如自体血清和富血小板血浆。
  • 新兴治疗如经鼻神经刺激的神经调节及新型药理治疗提供未来潜在选择;先进选项包括羊膜移植和复杂手术方法,为严重或难治性病例提供选择。

临床怎么用

  • 生活方式调整包括优化瞬目、膳食补充和环境调整,在长期管理中发挥关键作用。
  • 患者教育和治疗依从性对持续症状缓解仍然至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This report provides an evidence-based review of current strategies to manage dry eye disease (DED). First-line management focuses on methods to replenish, conserve, and stimulate the tear film, with an emphasis on ocular supplements, which remain the cornerstone of DED treatment. Meibomian gland dysfunction, a primary contributor to DED, is typically treated with warm compresses and a wide variety of in-office treatments, including device-driven technologies to warm the eyelids, intense pulsed light therapy, low-level light therapy, and other new and emerging technologies. Lid hygiene treatments include lid wipes, anti-Demodex therapies, blepharoexfoliation, and topical antibiotics. DED caused by certain etiological drivers can benefit from anti-inflammatory therapies, including topical and oral corticosteroids, T-cell immunomodulatory drugs, and a wide variety of pharmacological agents, in addition to biologic tear substitutes such as autologous serum and platelet-rich plasma. Emerging therapies, such as neuromodulation via nasal neurostimulation and novel pharmacological treatments, offer potential future options. Advanced options, including amniotic membrane grafts and complex surgical methods, provide options for severe or refractory cases. Lifestyle modifications, including optimized blinking, dietary supplementation, and environmental adjustments, play a crucial role in long-term management. Patient education and adherence to treatment regimens remain essential for sustained symptom relief. The TFOS DEWS III prescribing algorithm provides an evidence-based framework to offer guidance to clinicians in selecting relevant interventions based on disease etiology that aim to provide targeted management of the relevant DED subtype(s) that an individual is experiencing.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and Therapy. Am J Ophthalmol. 2025. PMID: 40467022. doi:10.1016/j.ajo.2025.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。